[조사 보고서] 세계의 체외 독성 검사 시장 (~2028년) : 제품 및 서비스별 (분석법 (ELISA, 웨스턴블롯), 기기, 소모품, 소프트웨어), 독성 종점별 (ADME, 유전 독성, 세포 독성), 기술별, 방법론별, 산업별 (제약, 화장품)

■ 영문 제목 : In Vitro Toxicology Testing Market by Product & Service (Assays (ELISA & Western Blot), Equipment, Consumable, Software), Toxicity Endpoints (ADME, Genotoxicity, Cytotoxicity), Technology, Method, Industry (Pharma, Cosmetics) - Global Forecast to 2028
	■ 상품코드 : BT2373-23 ■ 조사/발행회사 : MarketsandMarkets ■ 발행일 : 2023년 10월 ■ 페이지수 : 414 ■ 작성언어 : 영문 ■ 보고서 형태 : PDF ■ 납품 방식 : Email (주문후 24시간내 납품) ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 바이오

■ 판매가격 / 옵션 (부가세 10% 별도)

Single User	USD4,950 ⇒환산￦6,682,500	견적의뢰/주문/질문
Multi User (Five User)	USD6,650 ⇒환산￦8,977,500	견적의뢰/주문/질문
Corporate License	USD8,150 ⇒환산￦11,002,500	견적의뢰/구입/질문

※가격옵션 설명
- 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다.
- 지불방법은 계좌이체/무통장입금 또는 카드결제입니다.

"세계의 체외 독성 검사 시장은 예측 기간 중 연평균 성장률 9.5%을 기록하여, 2023년 108억 달러에서 2028년 171억 달러에 이를 것으로 전망됩니다."이 시장의 성장은 독물학 기기의 기술적 진보, 조기 독성 검출을 목표로 한 연구 개발 노력, 체외 독성 검사법을 이용한 창약과 개인화 의료에 대한 주목의 높아짐, 예측 독물학에 대한 관심의 증가로 인한 것으로 간주됩니다.

“2022년 제품 및 서비스별 점유율은 소모품 세그먼트가 최대을 기록했습니다.”
2022년 전세계 체외 독성 검사 시장에서 소모품 세그먼트는 제품 및 서비스에서 가장 큰 점유율을 차지했습니다. 의약품, 식품, 화장품, 화학품 등 업계 전반에 걸쳐 제품의 안전성을 향상시키는 것에 대한 주목이 높아지고 있는 것 등이 체외 독성 검사 시장에서 소모품의 수요를 촉진하고 있습니다. 또한 고품질 시약에 대한 수요 증가와 체외 독성 검사에서 배지 및 시약의 반복 사용도 이 시장의 성장을 뒷받침하고 있습니다. 또한 소모품 시장의 시장 점유율은 다양한 산업에서 체외 독성 검사의 도입이 진행됨에 따라 확대 될 것으로 예상됩니다.

“2023-2028년 예측 기간 동안 유럽이 계속 체외 독성 검사 시장을 장악할것으로 전망됩니다.”
이 지역에서 동물 실험을 금지하는 것은 모든 산업에서 시험관 내 독성 시험의 채택을 촉진하는 주요 요인입니다.
2022년 세계의 체외 독성 검사 시장은 유럽이 지배적이었습니다. 이러한 이점은 33개가 넘는 과학시설과 연구센터가 존재하며 종종 화장품 제조업체와 관련되어 역동적이고 고도로 혁신적인 화장품 산업이 육성되고 있기 때문입니다. 게다가 이 지역에서는 생물제제나 선진적인 제형에 대한 투자가 증가하고 있으며, 그 원인은 다수의 블록버스터 의약품의 특허 끊김이 가까이 다가오고 있습니다. 일반적으로 10~12년에 이르는 의약품 개발 프로세스를 가속화할 필요성이 증가하는 것은 시험관내 독성 시험에 대한 수요를 더욱 높여 줍니다. 특히 유럽연합(EU)은 규제 목적의 고급 체외 독성 검사 프로토콜의 개발과 검증을 위한 연구를 지원하는 최전선에 있습니다. 그 결과 유럽 시장은 신약 및 개인 케어 제품 개발, 동물 실험 대체 방법을 찾는 EU 회원국의 연구 개발 노력, 동물 실험이 이루어진 화장품 금지 등으로 성장을 목격하고 있습니다.

이 보고서를 위해 실시한 1차 인터뷰는 다음과 같이 분류됩니다.
- 응답자별 공급측: 70%, 수요측: 30%
- 직책별 관리직: 45%, CXO 및 이사: 30%, 경영 간부: 25%
- 지역별 북미: 40%, 유럽: 25%, 아시아 태평양: 20%, 중남미: 10%, 중동 및 아프리카: 5%

리포트 게재 기업은 다음과 같습니다.
• Thermo Fisher Scientific Inc. (US)
• Merck KGaA (Germany)
• Eurofins Scientific (Luxembourg)
• Laboratory Corporation of America Holdings (US)
• Charles River Laboratories (US)
• SGS SA (Switzerland)
• Bio-Rad Laboratories, Inc. (US)
• Evotec SE (Germany)
• Promega Corporation (US)
• Catalent, Inc. (US)
• Agilent Technologies, Inc. (US)
• Intertek Group plc (UK)
• Revvity (US)
• Inotiv (US)
• BioIVT (US)
• Lonza (Switzerland)
• Creative Biolabs (US)
• Shanghai Medicilon Inc. (China)
• Creative Bioarray (US)
• Aragen Life Sciences Ltd. (India)
• Enzo Biochem Inc. (US)
• Microbac Laboratories, Inc. (US)
• Vimta Labs Ltd. (India)
• Pacific BioLabs Inc. (US)
• MB Research Laboratories (US)

조사 범위:
이 연구 보고서는 체외 독성 검사 시장, 제품 및 서비스 (소모품, 분석, 장비, 소프트웨어, 서비스), 독성 종점 및 시험 (흡수, 분포, 대사, 배설 (ADME), 피부 자극, 부식 성, 감작성, 유전독성, 세포독성, 안독성, 장기독성, 광독성, 경피독성, 기타 독성 엔드포인트 및 시험), 산업(제약 및 바이오의약품, 기타 독성 엔드포인트 및 시험, 기타 독성 종점 및 시험), 산업 (제약 및 바이오 의약품, 소비자 케어, 식품 및 기타 산업 (화학 및 의료 기기 산업 포함)), 기술 (세포 배양, 높은 처리량 스크리닝, 독소 유전학), 방법 ( 세포 검정, 생화학 검정, 분자 독성 검정, 생체외 모델, 인실리코 모델)별로 분류하고 있습니다.
이 보고서는 체외 독성 검사 시장의 성장을 형성하는 촉진 요인, 동향, 도전, 기회 등 주요 영향 요인에 대한 자세한 정보를 다룹니다. 주요 업계 플레이어를 포괄적으로 분석하여 비즈니스 개요, 제품, 주요 전략, 제휴, 파트너십 및 계약에 대한 통찰력을 제공합니다. 또한 시험관 내 독물 검사 시장에서 신제품 출시, 합병, 인수 등의 최근 동향에 대해서도 다루고 있습니다.

보고서 구매의 주요 이점:
이 보고서는 체외 독성 검사 시장 전체와 그 하위 세그먼트에 대한 수익의 가장 가까운 근사치를 제공하여 시장 리더 / 신규 진출자를 지원합니다. 또한 이해관계자들이 경쟁 상황을 더 잘 이해하고 통찰력을 얻어 비즈니스를 더 잘 파악하고 적절한 시장 진입 전략을 수립할 수 있습니다. 이 보고서는 이해관계자가 시장의 맥동을 이해하고 주요 시장 촉진 요인, 저해 요인, 기회 및 과제에 대한 정보를 제공할 수 있도록 합니다.

이 보고서는 다음 포인트에 대한 통찰력을 제공합니다.
- 주요 촉진요인(동물실험에 대한 사회적 저항의 증가, 기술의 진보, 조기단계에서의 독성 검출을 목표로 하는 연구개발 노력) 저항, 생체내 조건의 복잡성을 확립할 수 없는 것, 복잡한 엔드포인트를 연구하기 위한 in vitro 모델의 부족), 기회(in vitro법을 이용한 창약과 개별화 의료에 대한 주목의 높아짐, 독성 데이터베이스 증가, 예측 독성학에 대한 관심의 증가) 및 시장 성장에 영향을 미치는 과제(데이터 가용성 및 검증 부족, 데이터 분석 및 관리 복잡성)응 분석하고 있습니다.
- 제품 / 서비스 개발 / 혁신 : 체외 독성 검사 시장에서 새로 출시 된 제품 / 서비스에 대한 자세한 통찰력을 제공합니다.
- 시장 개발 : 유리한 시장에 대한 포괄적인 정보 - 본 보고서는 다양한 지역의 시장을 분석합니다.
- 시장 다양화 : 시험관 내 독물 검사 시장에서 신제품, 미개척 지역, 최근 개발 및 투자에 대한 포괄적 인 정보를 게시합니다.
- 경쟁사 평가: Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Eurofins Scientific (Luxembourg), Laboratory Corporation of America Holdings (US), Charles River Laboratories (US), SGS SA (Switzerland), Bio -Rad Laboratories, Inc. (US), Evotec SE (Germany), Promega Corporation (US), Catalent, Inc. (US), Agilent Technologies, Inc. (US), Intertek Group plc (UK), Revvity (US) , Inotiv (US), BioIVT (US), Lonza (Switzerland), Creative Biolabs (US), Shanghai Medicilon Inc. (China), Creative Bioarray (US), Aragen Life Sciences Ltd. (India), Enzo Biochem Inc. ( US), Microbac Laboratories, Inc. (US), Vimta Labs Ltd. (India), Pacific BioLabs Inc. (US), 및 MB Research Laboratories (US) 등이 시장에 진출하고 있습니다.

■ 보고서 개요

1. 소개
2. 조사 방법
3. 개요
4. 프리미엄 인사이트
5. 시장 개요
6. 세계의 체외 독성 검사 시장 분석 : 제품 및 서비스별
7. 세계의 체외 독성 검사 시장 분석 : 독성 엔드포인트별
8. 세계의 체외 독성 검사 시장 분석 : 산업별
9. 세계의 체외 독성 검사 시장 분석 : 기술별
10. 세계의 체외 독성 검사 시장 분석 : 수법별
11. 세계의 체외 독성 검사 시장 분석 : 지역별
12. 경쟁 현황
13. 기업 정보
14. 부록

■ 보고서 목차

1 INTRODUCTION 49
1.1 STUDY OBJECTIVES 49
1.2 MARKET DEFINITION 49
1.2.1 INCLUSIONS AND EXCLUSIONS OF STUDY 50
1.2.2 MARKETS COVERED 51
FIGURE 1 IN VITRO TOXICOLOGY TESTING MARKET SEGMENTATION 51
1.2.3 YEARS CONSIDERED 52
1.3 CURRENCY 52
1.4 STAKEHOLDERS 52
1.5 LIMITATIONS 53
1.6 SUMMARY OF CHANGES 53
2 RESEARCH METHODOLOGY 55
2.1 RESEARCH DATA 55
FIGURE 2 RESEARCH DESIGN 55
2.1.1 SECONDARY DATA 56
2.1.2 PRIMARY DATA 56
FIGURE 3 IN VITRO TOXICOLOGY TESTING MARKET: BREAKDOWN OF PRIMARIES 57
2.2 MARKET SIZE ESTIMATION 58
FIGURE 4 IN VITRO TOXICOLOGY TESTING: MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 58
FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 59
FIGURE 6 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE ANALYSIS, 2022 59
2.2.1 INSIGHTS FROM PRIMARIES 61
FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS 61
FIGURE 8 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 61
2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST 62
FIGURE 9 IN VITRO TOXICOLOGY TESTING MARKET: CAGR PROJECTIONS 63
FIGURE 10 IN VITRO TOXICOLOGY TESTING MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES 63
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 64
FIGURE 11 DATA TRIANGULATION METHODOLOGY 64
2.5 RESEARCH ASSUMPTIONS 65
2.6 RISK ANALYSIS 65
2.7 RECESSION IMPACT ANALYSIS 65
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH) 65
TABLE 2 US: HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 66
TABLE 3 US: HEALTH EXPENDITURE, 2023–2030 (USD MILLION) 67
3 EXECUTIVE SUMMARY 68
FIGURE 12 IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 68
FIGURE 13 IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICITY ENDPOINT & TEST, 2023 VS. 2028 (USD MILLION) 69
FIGURE 14 IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 70
FIGURE 15 IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2023 VS. 2028 (USD MILLION) 70
FIGURE 16 IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2023 VS. 2028 (USD MILLION) 71
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF IN VITRO TOXICOLOGY TESTING MARKET 72
4 PREMIUM INSIGHTS 73
4.1 IN VITRO TOXICOLOGY TESTING MARKET OVERVIEW 73
FIGURE 18 PUBLIC RESISTANCE AGAINST ANIMAL TESTING TO DRIVE MARKET 73
4.2 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD AND COUNTRY (2022) 74
FIGURE 19 CELLULAR ASSAYS ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC IN VITRO TOXICOLOGY TESTING MARKET IN 2022 74
4.3 IN VITRO TOXICOLOGY TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 75
FIGURE 20 GERMANY TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 75
4.4 IN VITRO TOXICOLOGY TESTING MARKET SHARE, BY PRODUCT & SERVICE, 2022 75
FIGURE 21 CONSUMABLES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 75
5 MARKET OVERVIEW 76
5.1 INTRODUCTION 76
5.2 MARKET DYNAMICS 76
FIGURE 22 IN VITRO TOXICOLOGY TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 76
TABLE 4 IN VITRO TOXICOLOGY TESTING MARKET: IMPACT ANALYSIS 77
5.2.1 MARKET DRIVERS 77
5.2.1.1 Growing public resistance against animal testing 77
FIGURE 23 HISTORY OF EU BAN ON ANIMAL TESTING FOR COSMETICS 78
5.2.1.2 Technological advancements 79
5.2.1.3 Research and development efforts aimed at early-stage toxicity detection 80
FIGURE 24 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 (USD BILLION) 81
5.2.2 MARKET RESTRAINTS 81
5.2.2.1 Resistance of certain regulatory bodies to embrace alternative approaches in toxicology testing 81
5.2.2.2 Failure to establish intricacies of in vivo conditions 82
5.2.2.3 Lack of in vitro models to study complex endpoints 82

5.2.3 MARKET OPPORTUNITIES 82
5.2.3.1 Growing focus on drug discovery and personalized medicine using in vitro methods 82
5.2.3.2 Increasing number of toxicology databases 83
TABLE 5 CHEMICAL TOXICITY DATABASES 84
5.2.3.3 Increasing focus on predictive toxicology 85
5.2.4 MARKET CHALLENGES 85
5.2.4.1 Lack of data availability and validation 85
5.2.4.2 Complexity in data analysis and management 86
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 86
FIGURE 25 REVENUE SHIFT & NEW POCKETS FOR IN VITRO TOXICOLOGY TESTING PRODUCT/SERVICE PROVIDERS 86
5.4 PRICING ANALYSIS 87
5.4.1 AVERAGE SELLING PRICE OF IN VITRO TOXICOLOGY TESTING PRODUCTS, BY KEY PLAYER, 2022 87
TABLE 6 AVERAGE SELLING PRICE OF IN VITRO TOXICOLOGY TESTING PRODUCTS, BY KEY PLAYER 87
5.4.2 AVERAGE SELLING PRICE OF IN VITRO TOXICOLOGY TESTING PRODUCTS, BY REGION, 2022 88
TABLE 7 AVERAGE SELLING PRICE OF IN VITRO TOXICOLOGY TESTING PRODUCTS, BY REGION 88
5.4.3 AVERAGE SELLING PRICE TREND 88
5.5 VALUE CHAIN ANALYSIS 89
FIGURE 26 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING PRODUCT DEVELOPMENT AND MANUFACTURING PHASE 89
5.6 SUPPLY CHAIN ANALYSIS 90
FIGURE 27 SUPPLY CHAIN ANALYSIS: IN VITRO TOXICOLOGY TESTING MARKET 90
5.7 ECOSYSTEM ANALYSIS 90
FIGURE 28 ECOSYSTEM ANALYSIS: IN VITRO TOXICOLOGY TESTING MARKET 91
TABLE 8 ECOSYSTEM FOR IN VITRO TOXICOLOGY TESTING MARKET 91
5.8 PATENT ANALYSIS 92
FIGURE 29 IN VITRO TOXICOLOGY TESTING MARKET: PATENTS GRANTED (JANUARY 2013–SEPTEMBER 2023) 93
5.9 TECHNOLOGY ANALYSIS 93
5.10 KEY CONFERENCES & EVENTS, 2023–2024 95
TABLE 9 IN VITRO TOXICOLOGY TESTING MARKET: DETAILED LIST OF CONFERENCES & EVENTS 95
5.11 REGULATORY LANDSCAPE 96
5.11.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 10 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 96
TABLE 11 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 97
TABLE 12 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 98
TABLE 13 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 99
5.11.2 REGULATORY SCENARIO 99
TABLE 14 IN VITRO TOXICOLOGY TESTING MARKET: REGULATORY SCENARIO 99
5.12 PORTER’S FIVE FORCES ANALYSIS 103
TABLE 15 PORTER’S FIVE FORCES ANALYSIS 103
5.12.1 THREAT OF NEW ENTRANTS 103
5.12.2 THREAT OF SUBSTITUTES 103
5.12.3 BARGAINING POWER OF SUPPLIERS 103
5.12.4 BARGAINING POWER OF BUYERS 104
5.12.5 INTENSITY OF COMPETITIVE RIVALRY 104
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 104
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 104
FIGURE 30 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF IN VITRO TOXICOLOGY TESTING 104
5.13.2 BUYING CRITERIA FOR IN VITRO TOXICITY TESTING 105
FIGURE 31 KEY BUYING CRITERIA FOR END USERS 105
6 IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE 106
6.1 INTRODUCTION 107
TABLE 16 IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 107
6.2 CONSUMABLES 107
6.2.1 INCREASING DEMAND FOR HIGH-QUALITY REAGENTS TO DRIVE MARKET 107
TABLE 17 IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 108
TABLE 18 EUROPE: IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 108
TABLE 19 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 20 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 21 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 109
TABLE 22 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 110
6.3 ASSAYS 110
TABLE 23 IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 111
TABLE 24 IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 111
TABLE 25 EUROPE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 26 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 112
TABLE 27 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 28 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 113
TABLE 29 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 113
6.3.1 BACTERIAL TOXICITY ASSAYS 114
6.3.1.1 High sample throughput and rapid response to toxicants to drive adoption 114
TABLE 30 BACTERIAL TOXICITY ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 114
TABLE 31 EUROPE: BACTERIAL TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 32 NORTH AMERICA: BACTERIAL TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 115
TABLE 33 ASIA PACIFIC: BACTERIAL TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 34 LATIN AMERICA: BACTERIAL TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 116
TABLE 35 MIDDLE EAST & AFRICA: BACTERIAL TOXICITY ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 116
6.3.2 ENZYME TOXICITY ASSAYS 117
6.3.2.1 Increasingly used in endocrine-disrupting studies 117
TABLE 36 ENZYME TOXICITY ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 117
TABLE 37 EUROPE: ENZYME TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 38 NORTH AMERICA: ENZYME TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 39 ASIA PACIFIC: ENZYME TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 118
TABLE 40 LATIN AMERICA: ENZYME TOXICITY ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 119
TABLE 41 MIDDLE EAST & AFRICA: ENZYME TOXICITY ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 119
6.3.3 CELL-BASED ELISA & WESTERN BLOTTING ASSAYS 119
6.3.3.1 Simple, fast, and cost-effective alternatives to large-scale and cost-intensive animal testing 119
TABLE 42 CELL-BASED ELISA & WESTERN BLOTTING ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 120
TABLE 43 EUROPE: CELL-BASED ELISA & WESTERN BLOTTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 44 NORTH AMERICA: CELL-BASED ELISA & WESTERN BLOTTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 121
TABLE 45 ASIA PACIFIC: CELL-BASED ELISA & WESTERN BLOTTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 46 LATIN AMERICA: CELL-BASED ELISA & WESTERN BLOTTING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 122
TABLE 47 MIDDLE EAST & AFRICA: CELL-BASED ELISA & WESTERN BLOTTING ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 122
6.3.4 RECEPTOR-BINDING ASSAYS 123
6.3.4.1 Suitable for high-throughput formats 123
TABLE 48 RECEPTOR-BINDING ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 123
TABLE 49 EUROPE: RECEPTOR-BINDING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 50 NORTH AMERICA: RECEPTOR-BINDING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 124
TABLE 51 ASIA PACIFIC: RECEPTOR-BINDING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 52 LATIN AMERICA: RECEPTOR-BINDING ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 125
TABLE 53 MIDDLE EAST & AFRICA: RECEPTOR-BINDING ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 125
6.3.5 TISSUE CULTURE ASSAYS 126
6.3.5.1 Increasing cost of animal studies to propel market 126
TABLE 54 TISSUE CULTURE ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 126
TABLE 55 EUROPE: TISSUE CULTURE ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 56 NORTH AMERICA: TISSUE CULTURE ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 57 ASIA PACIFIC: TISSUE CULTURE ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 127
TABLE 58 LATIN AMERICA: TISSUE CULTURE ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 128
TABLE 59 MIDDLE EAST & AFRICA: TISSUE CULTURE ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 128
6.3.6 OTHER ASSAYS 128
TABLE 60 OTHER ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 129
TABLE 61 EUROPE: OTHER ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 62 NORTH AMERICA: OTHER ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 63 ASIA PACIFIC: OTHER ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 64 LATIN AMERICA: OTHER ASSAYS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 130
TABLE 65 MIDDLE EAST & AFRICA: OTHER ASSAYS MARKET, BY REGION, 2021–2028 (USD MILLION) 130
6.4 SERVICES 131
6.4.1 LACK OF INFRASTRUCTURE AND EXPERTISE IN RESEARCH CENTERS TO SUPPORT MARKET GROWTH 131
TABLE 66 IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 131
TABLE 67 EUROPE: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 68 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 132
TABLE 69 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 70 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 133
TABLE 71 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION) 133
6.5 EQUIPMENT 134
6.5.1 ADOPTION OF ADVANCED TESTING EQUIPMENT TO MEET NEW REGULATORY STANDARDS TO PROPEL MARKET 134
TABLE 72 IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 135
TABLE 73 EUROPE: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 135
TABLE 74 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 75 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 76 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 136
TABLE 77 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING EQUIPMENT MARKET, BY REGION, 2021–2028 (USD MILLION) 137
6.6 SOFTWARE 137
6.6.1 CRUCIAL ROLE IN DECREASING ANALYSIS TIME AND EFFECTIVELY HANDLING SUBSTANTIAL DATA VOLUMES 137
TABLE 78 IN VITRO TOXICOLOGY TESTING SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 138
TABLE 79 EUROPE: IN VITRO TOXICOLOGY TESTING SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 138
TABLE 80 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 81 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 82 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 139
TABLE 83 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION) 140
7 IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICITY ENDPOINT & TEST 141
7.1 INTRODUCTION 142
TABLE 84 IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICITY ENDPOINT & TEST, 2021–2028 (USD MILLION) 142
7.2 ABSORPTION, DISTRIBUTION, METABOLISM, & EXCRETION 143
7.2.1 PRODUCES HIGHLY REPRODUCIBLE & ACCURATE DATA 143
TABLE 85 IN VITRO ADME TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 144
TABLE 86 EUROPE: IN VITRO ADME TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 87 NORTH AMERICA: IN VITRO ADME TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 144
TABLE 88 ASIA PACIFIC: IN VITRO ADME TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 89 LATIN AMERICA: IN VITRO ADME TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 145
TABLE 90 MIDDLE EAST & AFRICA: IN VITRO ADME TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 145
7.3 GENOTOXICITY 146
7.3.1 RIGOROUS REGULATORY REQUIREMENTS FOR NEW DRUGS TO AID MARKET GROWTH 146
TABLE 91 IN VITRO GENOTOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 147
TABLE 92 EUROPE: IN VITRO GENOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 93 NORTH AMERICA: IN VITRO GENOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 147
TABLE 94 ASIA PACIFIC: IN VITRO GENOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 95 LATIN AMERICA: IN VITRO GENOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148
TABLE 96 MIDDLE EAST & AFRICA: IN VITRO GENOTOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 148
7.4 SKIN IRRITATION, CORROSION, & SENSITIZATION 149
7.4.1 MAJOR ENDPOINTS STUDIED IN COSMETICS INDUSTRY 149
TABLE 97 IN VITRO SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 150
TABLE 98 EUROPE: IN VITRO SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 150
TABLE 99 NORTH AMERICA: IN VITRO SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 100 ASIA PACIFIC: IN VITRO SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 101 LATIN AMERICA: IN VITRO SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 151
TABLE 102 MIDDLE EAST & AFRICA: IN VITRO SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 152
7.5 CYTOTOXICITY 152
7.5.1 RISING NEED FOR BIOSAFETY TO SUPPORT MARKET GROWTH 152
TABLE 103 IN VITRO CYTOTOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 153
TABLE 104 EUROPE: IN VITRO CYTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 105 NORTH AMERICA: IN VITRO CYTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 153
TABLE 106 ASIA PACIFIC: IN VITRO CYTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 107 LATIN AMERICA: IN VITRO CYTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 154
TABLE 108 MIDDLE EAST & AFRICA: IN VITRO CYTOTOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 154
7.6 OCULAR TOXICITY 155
7.6.1 IN VITRO AND EX VIVO TECHNIQUES INCREASINGLY GAINING ATTENTION FOR EVALUATION OF OCULAR TOXICITY 155
TABLE 109 IN VITRO OCULAR TOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 155
TABLE 110 EUROPE: IN VITRO OCULAR TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 111 NORTH AMERICA: IN VITRO OCULAR TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 112 ASIA PACIFIC: IN VITRO OCULAR TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 156
TABLE 113 LATIN AMERICA: IN VITRO OCULAR TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 157
TABLE 114 MIDDLE EAST & AFRICA: IN VITRO OCULAR TOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 157
7.7 ORGAN TOXICITY 157
7.7.1 FASTEST-GROWING SEGMENT OF MARKET 157
TABLE 115 IN VITRO ORGAN TOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 158
TABLE 116 EUROPE: IN VITRO ORGAN TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 158
TABLE 117 NORTH AMERICA: IN VITRO ORGAN TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 118 ASIA PACIFIC: IN VITRO ORGAN TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 119 LATIN AMERICA: IN VITRO ORGAN TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 159
TABLE 120 MIDDLE EAST & AFRICA: IN VITRO ORGAN TOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 160
7.8 DERMAL TOXICITY 160
7.8.1 ONGOING GOVERNMENT INITIATIVES AND CHANGES IN REGULATORY GUIDELINES TO SUPPORT MARKET GROWTH 160
TABLE 121 IN VITRO DERMAL TOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 161
TABLE 122 EUROPE: IN VITRO DERMAL TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 123 NORTH AMERICA: IN VITRO DERMAL TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 161
TABLE 124 ASIA PACIFIC: IN VITRO DERMAL TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 125 LATIN AMERICA: IN VITRO DERMAL TOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 162
TABLE 126 MIDDLE EAST & AFRICA: IN VITRO DERMAL TOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 162
7.9 PHOTOTOXICITY 163
7.9.1 ESTABLISHED NON-ANIMAL TECHNIQUES EMPLOYED TO ASSESS PHOTOTOXICITY OF COSMETICS, PHARMACEUTICALS, AND CHEMICALS 163
TABLE 127 IN VITRO PHOTOTOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 163
TABLE 128 EUROPE: IN VITRO PHOTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 129 NORTH AMERICA: IN VITRO PHOTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 164
TABLE 130 ASIA PACIFIC: IN VITRO PHOTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 131 LATIN AMERICA: IN VITRO PHOTOTOXICITY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 165
TABLE 132 MIDDLE EAST & AFRICA: IN VITRO PHOTOTOXICITY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 165
7.10 OTHER ENDPOINTS & TESTS 166
TABLE 133 OTHER IN VITRO ENDPOINTS & TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 166
TABLE 134 EUROPE: OTHER IN VITRO ENDPOINTS & TESTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 135 NORTH AMERICA: OTHER IN VITRO ENDPOINTS & TESTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 167
TABLE 136 ASIA PACIFIC: OTHER IN VITRO ENDPOINTS & TESTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 137 LATIN AMERICA: OTHER IN VITRO ENDPOINTS & TESTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 168
TABLE 138 MIDDLE EAST & AFRICA: OTHER IN VITRO ENDPOINTS & TESTS MARKET, BY REGION, 2021–2028 (USD MILLION) 168
8 IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY 169
8.1 INTRODUCTION 170
TABLE 139 IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 170
8.2 PHARMACEUTICAL & BIOPHARMACEUTICAL 170
8.2.1 GROWING R&D EXPENDITURE TO FAVOR MARKET GROWTH 170
TABLE 140 IN VITRO TOXICOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRY, BY REGION, 2021–2028 (USD MILLION) 171
TABLE 141 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 142 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 172
TABLE 143 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 144 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 173
TABLE 145 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL INDUSTRY, BY REGION, 2021–2028 (USD MILLION) 173

8.3 CONSUMER CARE 174
8.3.1 GROWING DEMAND FOR CRUELTY-FREE COSMETICS AND PERSONAL CARE PRODUCTS TO DRIVE MARKET 174
TABLE 146 IN VITRO TOXICOLOGY TESTING MARKET FOR CONSUMER CARE INDUSTRY, BY REGION, 2021–2028 (USD MILLION) 175
TABLE 147 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR CONSUMER CARE INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 175
TABLE 148 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CONSUMER CARE INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 149 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR CONSUMER CARE INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 150 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CONSUMER CARE INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 176
TABLE 151 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CONSUMER CARE INDUSTRY, BY REGION, 2021–2028 (USD MILLION) 177
8.4 FOOD 177
8.4.1 INCREASING FOCUS ON FOOD SAFETY TO PROPEL MARKET 177
TABLE 152 TYPES OF TOXICOLOGY TESTS FOR FOOD 178
TABLE 153 IN VITRO TOXICOLOGY TESTING MARKET FOR FOOD INDUSTRY, BY REGION, 2021–2028 (USD MILLION) 179
TABLE 154 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 179
TABLE 155 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 156 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 157 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR FOOD INDUSTRY, BY COUNTRY, 2021–2028 (USD MILLION) 180
TABLE 158 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR FOOD INDUSTRY, BY REGION, 2021–2028 (USD MILLION) 181
8.5 OTHER INDUSTRIES 181
TABLE 159 IN VITRO TOXICOLOGY TESTING MARKET FOR OTHER INDUSTRIES, BY REGION, 2021–2028 (USD MILLION) 182
TABLE 160 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR OTHER INDUSTRIES, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 161 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR OTHER INDUSTRIES, BY COUNTRY, 2021–2028 (USD MILLION) 183
TABLE 162 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR OTHER INDUSTRIES, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 163 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR OTHER INDUSTRIES, BY COUNTRY, 2021–2028 (USD MILLION) 184
TABLE 164 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR OTHER INDUSTRIES, BY REGION, 2021–2028 (USD MILLION) 184

9 IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY 185
9.1 INTRODUCTION 186
TABLE 165 IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186
9.2 CELL CULTURE 186
9.2.1 MOST PREFERRED TECHNIQUE FOR TOXICITY TESTING 186
TABLE 166 IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE, BY REGION, 2021–2028 (USD MILLION) 187
TABLE 167 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 187
TABLE 168 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 169 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 170 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE, BY COUNTRY, 2021–2028 (USD MILLION) 188
TABLE 171 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CELL CULTURE, BY REGION, 2021–2028 (USD MILLION) 189
9.3 HIGH-THROUGHPUT SCREENING 189
9.3.1 INCREASING USE OF HIGH-CONTENT IMAGING TECHNOLOGIES IN TOXICITY TESTING TO BOOST MARKET GROWTH 189
TABLE 172 IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2021–2028 (USD MILLION) 190
TABLE 173 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION) 190
TABLE 174 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 175 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 176 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH-THROUGHPUT SCREENING, BY COUNTRY, 2021–2028 (USD MILLION) 191
TABLE 177 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR HIGH-THROUGHPUT SCREENING, BY REGION, 2021–2028 (USD MILLION) 192
9.4 TOXICOGENOMICS 192
9.4.1 TECHNOLOGICAL ADVANCEMENTS IN PROTEOMICS AND GENOMICS TO DRIVE MARKET 192
TABLE 178 IN VITRO TOXICOLOGY TESTING MARKET FOR TOXICOGENOMICS, BY REGION, 2021–2028 (USD MILLION) 193
TABLE 179 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 193
TABLE 180 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 181 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 182 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 194
TABLE 183 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR TOXICOGENOMICS, BY REGION, 2021–2028 (USD MILLION) 195
10 IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD 196
10.1 INTRODUCTION 197
TABLE 184 IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 197
10.2 CELLULAR ASSAYS 197
10.2.1 DEVELOPMENT OF MULTIPARAMETER ASSAYS TO PROVIDE SIGNIFICANT GROWTH OPPORTUNITIES FOR MARKET PLAYERS 197
TABLE 185 IN VITRO TOXICOLOGY TESTING MARKET FOR CELLULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION) 198
TABLE 186 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR CELLULAR ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 198
TABLE 187 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CELLULAR ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 188 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR CELLULAR ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 189 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CELLULAR ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 199
TABLE 190 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR CELLULAR ASSAYS, BY REGION, 2021–2028 (USD MILLION) 200
10.3 BIOCHEMICAL ASSAYS 200
10.3.1 HELP REFLECT UPON UNNATURAL CHANGES INDUCED BY TEST SUBSTANCES 200
TABLE 191 IN VITRO TOXICOLOGY TESTING MARKET FOR BIOCHEMICAL ASSAYS, BY REGION, 2021–2028 (USD MILLION) 201
TABLE 192 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR BIOCHEMICAL ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 201
TABLE 193 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR BIOCHEMICAL ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 194 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR BIOCHEMICAL ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 195 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR BIOCHEMICAL ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 202
TABLE 196 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR BIOCHEMICAL ASSAYS, BY REGION, 2021–2028 (USD MILLION) 203
10.4 MOLECULAR TOXICOLOGY ASSAYS 203
10.4.1 RISING INVESTMENTS IN MOLECULAR TOXICOLOGY TECHNOLOGIES TO DRIVE MARKET 203
TABLE 197 IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR TOXICOLOGY ASSAYS, BY REGION, 2021–2028 (USD MILLION) 204
TABLE 198 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR TOXICOLOGY ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 204
TABLE 199 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR TOXICOLOGY ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 200 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR TOXICOLOGY ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 201 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR TOXICOLOGY ASSAYS, BY COUNTRY, 2021–2028 (USD MILLION) 205
TABLE 202 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR MOLECULAR TOXICOLOGY ASSAYS, BY REGION, 2021–2028 (USD MILLION) 206
10.5 EX VIVO MODELS 206
10.5.1 RISING DEMAND FOR ALTERNATIVES TO ANIMAL TESTING TO DRIVE MARKET 206
TABLE 203 IN VITRO TOXICOLOGY TESTING MARKET FOR EX VIVO MODELS, BY REGION, 2021–2028 (USD MILLION) 207
TABLE 204 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR EX VIVO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 207
TABLE 205 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR EX VIVO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 208
TABLE 206 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR EX VIVO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 208
TABLE 207 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR EX VIVO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 208
TABLE 208 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR EX VIVO MODELS, BY REGION, 2021–2028 (USD MILLION) 209
10.6 IN SILICO MODELS 209
10.6.1 HELP REDUCE NUMBER OF SAMPLES TESTED 209
TABLE 209 IN VITRO TOXICOLOGY TESTING MARKET FOR IN SILICO MODELS, BY REGION, 2021–2028 (USD MILLION) 210
TABLE 210 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET FOR IN SILICO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 210
TABLE 211 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR IN SILICO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 211
TABLE 212 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET FOR IN SILICO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 211
TABLE 213 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET FOR IN SILICO MODELS, BY COUNTRY, 2021–2028 (USD MILLION) 211
TABLE 214 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET FOR IN SILICO MODELS, BY REGION, 2021–2028 (USD MILLION) 212

11 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION 213
11.1 INTRODUCTION 214
TABLE 215 IN VITRO TOXICOLOGY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 214
11.2 EUROPE 214
FIGURE 32 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET SNAPSHOT 215
TABLE 216 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 216
TABLE 217 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 216
TABLE 218 EUROPE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 217
TABLE 219 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 217
TABLE 220 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 218
TABLE 221 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 218
TABLE 222 EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 219
11.2.1 GERMANY 219
11.2.1.1 Well-established pharmaceuticals industry to support market growth 219
TABLE 223 GERMANY: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 220
TABLE 224 GERMANY: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 220
TABLE 225 GERMANY: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 221
TABLE 226 GERMANY: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 221
TABLE 227 GERMANY: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 222
TABLE 228 GERMANY: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 222
11.2.2 UK 222
11.2.2.1 Rising focus on research activities and academia-industry partnerships to drive market 222
TABLE 229 UK: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 223
TABLE 230 UK: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 224
TABLE 231 UK: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 224
TABLE 232 UK: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 225
TABLE 233 UK: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 225
TABLE 234 UK: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 225
11.2.3 FRANCE 226
11.2.3.1 Increasing government funding for proteomics and genomics research to drive market 226
TABLE 235 FRANCE: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 227
TABLE 236 FRANCE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 227
TABLE 237 FRANCE: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 228
TABLE 238 FRANCE: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 228
TABLE 239 FRANCE: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 229
TABLE 240 FRANCE: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 229
11.2.4 ITALY 229
11.2.4.1 Increasing life sciences research to propel market 229
TABLE 241 ITALY: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 230
TABLE 242 ITALY: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 230
TABLE 243 ITALY: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 231
TABLE 244 ITALY: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 231
TABLE 245 ITALY: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 232
TABLE 246 ITALY: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 232
11.2.5 SPAIN 232
11.2.5.1 Growing chemicals industry to support market growth 232
TABLE 247 SPAIN: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 233
TABLE 248 SPAIN: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 233
TABLE 249 SPAIN: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 234
TABLE 250 SPAIN: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 234
TABLE 251 SPAIN: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 235
TABLE 252 SPAIN: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 235
11.2.6 REST OF EUROPE 235
TABLE 253 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 236
TABLE 254 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 237
TABLE 255 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 237
TABLE 256 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 238
TABLE 257 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 238
TABLE 258 REST OF EUROPE: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 239
11.2.7 RECESSION IMPACT 239
11.3 NORTH AMERICA 240
TABLE 259 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 240
TABLE 260 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 241
TABLE 261 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 241
TABLE 262 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 242
TABLE 263 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 242
TABLE 264 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 243
TABLE 265 NORTH AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 243
11.3.1 US 243
11.3.1.1 Growing focus on biomarker discovery and research in structure-based drug design to propel market 243
TABLE 266 US: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 245
TABLE 267 US: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 245
TABLE 268 US: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 246
TABLE 269 US: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 246
TABLE 270 US: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 247
TABLE 271 US: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 247
11.3.2 CANADA 247
11.3.2.1 Strong support to carry out R&D in pharmaceutical and proteomics fields to boost market growth 247
TABLE 272 CANADA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 248
TABLE 273 CANADA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 249
TABLE 274 CANADA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 249
TABLE 275 CANADA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 250
TABLE 276 CANADA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 250
TABLE 277 CANADA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 251
11.3.3 RECESSION IMPACT 251
11.4 ASIA PACIFIC 252
FIGURE 33 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET SNAPSHOT 253
TABLE 278 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 254
TABLE 279 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 254
TABLE 280 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 255
TABLE 281 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 255
TABLE 282 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 256
TABLE 283 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 256
TABLE 284 ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 257
11.4.1 CHINA 257
11.4.1.1 Increasing international pressure to ban animal testing methods to propel market 257
TABLE 285 CHINA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 258
TABLE 286 CHINA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 258
TABLE 287 CHINA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 259
TABLE 288 CHINA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 259
TABLE 289 CHINA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 260
TABLE 290 CHINA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 260
11.4.2 JAPAN 260
11.4.2.1 Rising demand for technologically advanced research products to drive market 260
TABLE 291 JAPAN: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 261
TABLE 292 JAPAN: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 262
TABLE 293 JAPAN: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 262
TABLE 294 JAPAN: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 263
TABLE 295 JAPAN: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 263
TABLE 296 JAPAN: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 263
11.4.3 INDIA 264
11.4.3.1 Growing focus of universities on avoiding use of animals to test cosmetic products to propel market 264
TABLE 297 INDIA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 265
TABLE 298 INDIA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 265
TABLE 299 INDIA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 266
TABLE 300 INDIA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 266
TABLE 301 INDIA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 267
TABLE 302 INDIA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 267
11.4.4 SOUTH KOREA 267
11.4.4.1 Growing focus of government to increase pharmaceutical spending to propel market growth 267
TABLE 303 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 268
TABLE 304 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 269
TABLE 305 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 269
TABLE 306 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 270
TABLE 307 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 270
TABLE 308 SOUTH KOREA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 271
11.4.5 REST OF ASIA PACIFIC 271
TABLE 309 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 272
TABLE 310 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 272
TABLE 311 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 273
TABLE 312 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 273
TABLE 313 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 274
TABLE 314 REST OF ASIA PACIFIC: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 274
11.4.6 RECESSION IMPACT 274
11.5 LATIN AMERICA 275
TABLE 315 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 276
TABLE 316 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 276
TABLE 317 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 277
TABLE 318 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 277
TABLE 319 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 278
TABLE 320 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 278
TABLE 321 LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 279
11.5.1 BRAZIL 279
11.5.1.1 Adoption of non-animal testing methods to propel market 279
TABLE 322 BRAZIL: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 280
TABLE 323 BRAZIL: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 280
TABLE 324 BRAZIL: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 281
TABLE 325 BRAZIL: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 281
TABLE 326 BRAZIL: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 282
TABLE 327 BRAZIL: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 282
11.5.2 MEXICO 282
11.5.2.1 Ban on animal testing for cosmetics to support market growth 282
TABLE 328 MEXICO: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 283
TABLE 329 MEXICO: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 284
TABLE 330 MEXICO: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 284
TABLE 331 MEXICO: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 285
TABLE 332 MEXICO: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 285
TABLE 333 MEXICO: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 286
11.5.3 REST OF LATIN AMERICA 286
TABLE 334 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 286
TABLE 335 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 287
TABLE 336 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 287
TABLE 337 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 288
TABLE 338 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 288
TABLE 339 REST OF LATIN AMERICA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 289
11.5.4 RECESSION IMPACT 289
11.6 MIDDLE EAST & AFRICA 289
TABLE 340 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY REGION, 2021–2028 (USD MILLION) 290
TABLE 341 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 290
TABLE 342 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 291
TABLE 343 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 291
TABLE 344 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 292
TABLE 345 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 292
TABLE 346 MIDDLE EAST & AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 293
11.6.1 MIDDLE EAST 293
11.6.1.1 Growing focus on AI-based technologies for drug discovery to drive market 293
TABLE 347 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 294
TABLE 348 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 294
TABLE 349 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 295
TABLE 350 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 295
TABLE 351 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 296
TABLE 352 MIDDLE EAST: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 296
11.6.2 AFRICA 296
11.6.2.1 Precision medicine initiatives to fuel market growth 296
TABLE 353 AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 297
TABLE 354 AFRICA: IN VITRO TOXICOLOGY TESTING ASSAYS MARKET, BY TYPE, 2021–2028 (USD MILLION) 297
TABLE 355 AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT & TEST, 2021–2028 (USD MILLION) 298
TABLE 356 AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 298
TABLE 357 AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY, 2021–2028 (USD MILLION) 299
TABLE 358 AFRICA: IN VITRO TOXICOLOGY TESTING MARKET, BY METHOD, 2021–2028 (USD MILLION) 299
11.6.3 RECESSION IMPACT 299
12 COMPETITIVE LANDSCAPE 301
12.1 OVERVIEW 301
12.2 STRATEGIES ADOPTED BY KEY PLAYERS 302
FIGURE 34 IN VITRO TOXICOLOGY TESTING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 302
12.3 REVENUE SHARE ANALYSIS 302
FIGURE 35 REVENUE SHARE ANALYSIS OF TOP PLAYERS IN IN VITRO TOXICOLOGY TESTING MARKET, 2018–2022 303
12.4 MARKET SHARE ANALYSIS 303
FIGURE 36 IN VITRO TOXICOLOGY TESTING MARKET SHARE, BY KEY PLAYER, 2022 304
TABLE 359 IN VITRO TOXICOLOGY TESTING MARKET: DEGREE OF COMPETITION 304
12.5 COMPANY EVALUATION MATRIX 305
12.5.1 STARS 306
12.5.2 EMERGING LEADERS 306
12.5.3 PERVASIVE PLAYERS 306
12.5.4 PARTICIPANTS 306
FIGURE 37 IN VITRO TOXICOLOGY TESTING MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 307
12.5.5 COMPANY FOOTPRINT 308
TABLE 360 OVERALL FOOTPRINT ANALYSIS OF COMPANIES (2022) 308
12.5.5.1 Product/Service footprint analysis 309
TABLE 361 PRODUCT/SERVICE FOOTPRINT ANALYSIS OF COMPANIES (2022) 309
12.5.5.2 Regional footprint analysis 310
TABLE 362 REGIONAL FOOTPRINT ANALYSIS OF COMPANIES (2022) 310
12.6 STARTUP/SME EVALUATION MATRIX 311
12.6.1 PROGRESSIVE COMPANIES 311
12.6.2 STARTING BLOCKS 311
12.6.3 RESPONSIVE COMPANIES 311
12.6.4 DYNAMIC COMPANIES 312
FIGURE 38 IN VITRO TOXICOLOGY TESTING MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022 312
12.6.5 COMPETITIVE BENCHMARKING 313
TABLE 363 IN VITRO TOXICOLOGY TESTING MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 313
TABLE 364 IN VITRO TOXICOLOGY TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 314
12.7 COMPETITIVE SCENARIO 315
TABLE 365 KEY PRODUCT/SERVICE LAUNCHES 315
TABLE 366 KEY DEALS 315
TABLE 367 OTHER KEY DEVELOPMENTS 317
13 COMPANY PROFILES 318
(Business Overview, Products & Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
13.1 MAJOR PLAYERS 318
13.1.1 THERMO FISHER SCIENTIFIC INC. 318
TABLE 368 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 318
FIGURE 39 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 319
13.1.2 AGILENT TECHNOLOGIES, INC. 328
TABLE 369 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 328
FIGURE 40 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 329
13.1.3 MERCK KGAA 334
TABLE 370 MERCK KGAA: BUSINESS OVERVIEW 334
FIGURE 41 MERCK KGAA: COMPANY SNAPSHOT (2022) 335
13.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS 339
TABLE 371 LABORATORY CORPORATION OF AMERICA HOLDINGS: BUSINESS OVERVIEW 339
FIGURE 42 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2022) 340
13.1.5 EUROFINS SCIENTIFIC 345
TABLE 372 EUROFINS SCIENTIFIC: BUSINESS OVERVIEW 345
FIGURE 43 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 346
13.1.6 CHARLES RIVER LABORATORIES 355
TABLE 373 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW 355
FIGURE 44 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2022) 356
13.1.7 SGS SA 363
TABLE 374 SGS SA: BUSINESS OVERVIEW 363
FIGURE 45 SGS SA: COMPANY SNAPSHOT (2022) 364
13.1.8 REVVITY 369
TABLE 375 REVVITY: BUSINESS OVERVIEW 369
FIGURE 46 REVVITY: COMPANY SNAPSHOT (2022) 370
13.1.9 BIO-RAD LABORATORIES, INC. 374
TABLE 376 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW 374
FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 375
13.1.10 LONZA 379
TABLE 377 LONZA: BUSINESS OVERVIEW 379
FIGURE 48 LONZA: COMPANY SNAPSHOT (2022) 380
13.1.11 EVOTEC SE 383
TABLE 378 EVOTEC SE: BUSINESS OVERVIEW 383
FIGURE 49 EVOTEC SE: COMPANY SNAPSHOT (2022) 384
13.1.12 CATALENT, INC. 394
TABLE 379 CATALENT, INC.: BUSINESS OVERVIEW 394
FIGURE 50 CATALENT, INC.: COMPANY SNAPSHOT (2022) 395
13.1.13 INTERTEK GROUP PLC 397
TABLE 380 INTERTEK GROUP PLC: BUSINESS OVERVIEW 397
FIGURE 51 INTERTEK GROUP PLC: COMPANY SNAPSHOT (2022) 397
13.1.14 INOTIV 399
TABLE 381 INOTIV: BUSINESS OVERVIEW 399
FIGURE 52 INOTIV: COMPANY SNAPSHOT (2022) 400
13.1.15 PROMEGA CORPORATION 404
TABLE 382 PROMEGA CORPORATION: BUSINESS OVERVIEW 404
13.2 OTHER PLAYERS 408
13.2.1 BIOIVT 408
TABLE 383 BIOIVT: COMPANY OVERVIEW 408
13.2.2 CREATIVE BIOLABS 409
TABLE 384 CREATIVE BIOLABS: COMPANY OVERVIEW 409
13.2.3 SHANGHAI MEDICILON INC. 410
TABLE 385 SHANGHAI MEDICILON INC.: COMPANY OVERVIEW 410
13.2.4 CREATIVE BIOARRAY 411
TABLE 386 CREATIVE BIOARRAY: COMPANY OVERVIEW 411
13.2.5 ARAGEN LIFE SCIENCES LTD. 412
TABLE 387 ARAGEN LIFE SCIENCES LTD.: COMPANY OVERVIEW 412
13.2.6 ENZO BIOCHEM INC. 414
TABLE 388 ENZO BIOCHEM INC.: COMPANY OVERVIEW 414
13.2.7 MICROBAC LABORATORIES, INC. 417
TABLE 389 MICROBAC LABORATORIES, INC.: COMPANY OVERVIEW 417
13.2.8 VIMTA LABS LTD. 418
TABLE 390 VIMTA LABS LTD.: COMPANY OVERVIEW 418
13.2.9 PACIFIC BIOLABS, INC. 419
TABLE 391 PACIFIC BIOLABS, INC.: COMPANY OVERVIEW 419
13.2.10 MB RESEARCH LABORATORIES 420
TABLE 392 MB RESEARCH LABORATORIES: COMPANY OVERVIEW 420
*Details on Business Overview, Products & Services Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
14 APPENDIX 421
14.1 DISCUSSION GUIDE 421
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 427
14.3 CUSTOMIZATION OPTIONS 429
14.4 RELATED REPORTS 429
14.5 AUTHOR DETAILS 430

※본 조사보고서 [세계의 체외 독성 검사 시장 (~2028년) : 제품 및 서비스별 (분석법 (ELISA, 웨스턴블롯), 기기, 소모품, 소프트웨어), 독성 종점별 (ADME, 유전 독성, 세포 독성), 기술별, 방법론별, 산업별 (제약, 화장품)] (코드 : BT2373-23) 판매에 관한 면책사항을 반드시 확인하세요.

※본 조사보고서 [세계의 체외 독성 검사 시장 (~2028년) : 제품 및 서비스별 (분석법 (ELISA, 웨스턴블롯), 기기, 소모품, 소프트웨어), 독성 종점별 (ADME, 유전 독성, 세포 독성), 기술별, 방법론별, 산업별 (제약, 화장품)] 에 대해서 E메일 문의는 여기를 클릭하세요.

*** 아래는 관련 보고서 소개입니다 ***

세계의 의료용 튜브 시장 (~2028년) : 재질별 (플라스틱, 고무, 특수 폴리머), 용도별 (벌크 일회용 튜브, 카테터 및 캐뉼라, 약물 전달 시스템, 특수 용도), 구조별, 지역별
CH4564-23 / MarketsandMarkets / 2023년 11월 / “세계의 의료용 튜브 시장은 2023년 106억 달러에서 연평균 성장률 8.2%로 성장하며, 2028년는 157억 달러에 이를 것으로 예측됩니다.”시장 추세의 확대, 응용 프로그램의 증가, 신흥 국가의 소비자 수요, 의료용 튜브 기술의 진보가...1. 소개 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 의료용 튜브 시장 분석 : 구조별 7. 세계의 의료용 튜브 시장 분석 : 재료별 8. 세계의 의료용 튜브 시장 분석 : 용도별 9. 세계의 의료용 튜브 시장 분석 : 지역별 10. 경쟁 현황 11. 기업...

세계의 조직 공학 시장 (~2028년) : 제품별 (스캐 폴드 (콜라겐, 줄기 세포)), 조직 이식편별 (동종 이식편, 자가 이식편, 이종 이식편), 재료별 (생물학적, 합성), 용도별 (정형외과, 피부과, 상처 치료, 심혈관)
BT8892-24 / MarketsandMarkets / 2023년 12월 / "글로벌 조직 공학 시장은 예측 기간 동안 연평균 15.3%의 성장률로 2023년 약 44억 달러에서 2028년 89억 달러에 이를 것으로 예측됩니다."이 시장의 성장은 첨단 조직 공학 솔루션 개발을 위한 자금 조달...1. 서론 2. 조사 방법 3. 개요 4. 프리미엄 인사이트 5. 시장 개요 6. 세계의 조직 공학 시장 규모 : 제품별 7. 세계의 조직 공학 시장 규모 : 재료별 8. 세계의 조직 공학 시장 규모 : 용도별 9. 세계의 조직 공학 시장 규모 : 최종 용도별 10. 세계의 조직 공학...

세계의 유전자형 분석 시장 (~2029년) : 제품 및 서비스별 (키트, 기기, 바이오인포매틱스), 기술별 (PCR, 시퀀싱, 마이크로어레이), 용도별 (약리 유전체학, 동물 유전학), 최종 용도별 (제약 및 바이오 테크놀로지 기업, 진단 연구소)
BT3397 / MarketsandMarkets / 2024년 6월 / ...“세계의 유전자형 분석 시장은 예측 기간 동안 13.8%의 연평균 성장률로 2024년 194억 달러에서 2029년 371억 달러로 성장할 것으로 예상됩니다.”기술의 발전과 DNA 시퀀싱 비용의 하락이 이 시장의 성장을 촉진할 것으로 예상됩니다. 최근 유전성 질환의 유병률 증가로 인해 업계는 더딘 속도로 성장하고 있습니다. 또한 맞춤형 의학 및 약물 개발 분야에서 유전자형 분석은...

세계의 동물용 초음파 시장 (~2029) : 종류별 (2D, 3D/4D, 도플러), 제품별 (휴대용 스캐너), 기술별 (디지털, 콘트라스트), 동물 종류별 (소형, 대형), 용도별 (산부인과, 순환기내과, 정형외과), 최종 용도별 (진료소, 병원)
MD7508 / MarketsandMarkets / 2024년 6월 / ...“세계의 동물용 초음파 시장은 2024년 3억 8,500만 달러에서 2029년 5억 3,900만 달러에 달할 것으로 예상되며, 2024년부터 2029년까지 7.0%의 CAGR로 성장할 것으로 전망됩니다.”동물 건강 인식 증가, 가축 인구 및 농업 관행 증가, 반려동물 소유 및 동물 건강 관리에 대한 지출 증가, 동물용 초음파 기술의 발전, 정부의 규제 및 이니셔티브 지원 등이...

글로벌 셀 카운팅 시장 (~2029) : 제품별, 소모품, 응용 분야별, 최종 사용자별
BT 3379 / MarketsandMarkets / 2025년 2월 / ...2023년 108억 2천만 달러 규모로 추정되는 글로벌 셀 카운팅 시장은 2024년 111억 2천만 달러, 2029년에는 161억 4천만 달러에 달할 것으로 예상되며, 연평균 7.7%의 높은 성장률을 보일 것으로 전망됩니다. 기술의 발전, 연구 이니셔티브의 증가, 정밀 진단에 대한 수요 증가가 글로벌 셀 카운팅 시장을 주도하는 핵심 요소입니다. 형광 기반 시스템과 같은 자동화...

※당 사이트에 없는 보고서도 취급 가능한 경우가 많으니 문의 주세요!